Spero Therapeutics, Inc. Stock

$2.32

0.64% today

Nasdaq, Jul 28, 08:46 pm CET

ISIN

US84833T1034

Symbol

SPRO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Spero Therapeutics, Inc. Stock price

$2.33

-9.78 80.76% 5Y

Nasdaq, Closing price Fri, Jul 25 2025

-0.02 0.85%

ISIN

US84833T1034

Symbol

SPRO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$130.3m

Enterprise Value

$81.4m

Net debt

positive

Cash

$48.9m

Shares outstanding

55.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

2.9 | 21.6

EV/Sales

1.8 | 13.5

EV/FCF

negative

P/B

3.9

Financial Health

Equity Ratio

41.7%

Return on Equity

-148.7%

ROCE

-150.5%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$44.6m | $6.0m

EBITDA

- | -

EBIT

$-73.1m | $-82.1m

Net Income

$-69.8m | $-65.6m

Free Cash Flow

$-33.4m

Growth (TTM | estimate)

Revenue

-59.8% | -87.5%

EBITDA

- | -

EBIT

-436.2% | -13.3%

Net Income

-398.1% | 4.4%

Free Cash Flow

-134.9%

EPS

$-1.3

FCF per Share

$-0.6

Short interest

2.7%

Employees

Rev per Employee

$1.5m

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Get Started for Free Today

Spero Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Spero Therapeutics, Inc. forecast:

6x Buy

67%

3x Hold

33%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Spero Therapeutics, Inc. forecast:

Buy

67%

Hold

33%

Analyst Estimates with Stock Price Targets

Financial data from Spero Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	45 45	60% 60% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	25 25	2% 2% 55%
- Research and Development Expense	93 93	56% 56% 209%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-73 -73	436% 436% -164%
Net Profit	-70 -70	398% 398% -156%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Spero Therapeutics, Inc. Stock News

Positive

Seeking Alpha

●

about 2 months ago

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

Based on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a license partner, will take over commercialization. Approval is expected to trigger in total of $175 million in milestone payments over the next 12 months.

Neutral

GlobeNewsWire

●

2 months ago

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US 1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs 2 Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administr...

Neutral

GlobeNewsWire

●

3 months ago

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

More Spero Therapeutics, Inc. News

Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Esther Rajavelu
Employees	32
Founded	2013
Website	sperotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now